Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a condition characterized by fat buildup in the liver. MAFLD can evolve in severity to noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), which is chronic, progressive, and potentially life-threatening. Current practice guidance recommends lifestyle interventions and medications for managing comorbidities. In 2024, resmetirom became the first FDA-approved treatment for adults who have noncirrhotic MASH with moderate-to-advanced fibrosis. Ongoing clinical trials are evaluating resmetirom's safety and efficacy in patients with cirrhosis. The pharmacist's key responsibilities when engaging with patients who are prescribed resmetirom for MASH include encouraging healthy lifestyle changes, educating about potential side effects, identifying and counseling on potential drug interactions, and facilitating drug accessibility.